Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Licensed Monoclonal Antibodies and Associated Challenges Publisher Pubmed



Khan AH1 ; Sadroddiny E1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, No 88 Italia st., Tehran, Iran

Source: Human Antibodies Published:2015


Abstract

Monoclonal antibodies (mAbs) are the leading class of targeted therapeutics and remarkably effective in addressing autoimmune diseases, inflammations, infections, and various types of cancer. Several mAbs approved by US food and drug administration (FDA), are available on the market and a number are pending for approval. Luckily, FDA approved mAbs have played a pivotal role in the treatment and prevention of lethal diseases. However, claiming that licensed mAbs are 100% safe is still debatable, because infections, malignancies, anaphylactoid, and anaphylactic reactions are the more frequently associated adverse events. To evaluate benefit to risk ratio of mAbs, it is important for the clinical research staff or physicians to monitor and follow-up the patients who are receiving mAbs dozes. It is recommended that patients, physicians, biopharmaceutical companies, and researchers should keep in touch to highlight and resolve antibody-based adverse events. In this review we underscore the associated challenges of mAbs, approved by FDA from 2007-2014. © 2015 IOS Press and the authors. All rights reserved.
Related Docs
View other Related Docs
1. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
2. Monoclonal Antibodies for Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
3. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
4. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
5. Immunopathology and Immunotherapy for Breast Cancer, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
6. Efficacy and Safety of Immune Checkpoint Inhibitors and Cytokine Therapy in Autoimmune Diseases, Translational Autoimmunity: Treatment of Autoimmune Diseases (2022)
7. Adcs, As Novel Revolutionary Weapons for Providing a Step Forward in Targeted Therapy of Malignancies, Current Drug Delivery (2020)
8. The Applications of Anti-Cd20 Antibodies to Treat Various B Cells Disorders, Biomedicine and Pharmacotherapy (2019)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (15)
Babak Negahdari (2)
Other Related Docs
9. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2015)
10. Immunotherapy for Breast Cancer Treatment, Iranian Biomedical Journal (2021)
11. Antibody-Drug Therapeutic Conjugates: Potential of Antibody-Sirnas in Cancer Therapy, Journal of Cellular Physiology (2019)
12. Synthesized Anti-Her2 Trastuzumab-Mcc-Dm1 Conjugate: An Evaluation of Efficacy and Cytotoxicity, Iranian Journal of Immunology (2023)
13. A Review on Leukemia and Ipsc Technology: Application in Novel Treatment and Future, Current Stem Cell Research and Therapy (2018)
14. Adverse Events Following Administration of Anti-Ctla4 Antibody Ipilimumab, Frontiers in Oncology (2021)
15. Muc1 Is a Potential Target to Overcome Trastuzumab Resistance in Breast Cancer Therapy, Cancer Cell International (2022)
16. Potential Role of Regulatory B Cells in Immunological Diseases, Immunology Letters (2019)
17. An Overview on Display Systems (Phage, Bacterial, and Yeast Display) for Production of Anticancer Antibodies; Advantages and Disadvantages, International Journal of Biological Macromolecules (2022)
18. Immune Checkpoint Blockade in Melanoma: Advantages, Shortcomings and Emerging Roles of the Nanoparticles, International Immunopharmacology (2022)
19. Ofatumumab Monoclonal Antibody Affinity Maturation Through in Silico Modeling, Iranian Biomedical Journal (2018)
20. Genetically Engineered Mesenchymal Stem Cells: Targeted Delivery of Immunomodulatory Agents for Tumor Eradication, Cancer Gene Therapy (2020)
21. Immune Checkpoint Inhibitors Therapy As the Game-Changing Approach for Pediatric Lymphoma: A Brief Landscape, Critical Reviews in Oncology/Hematology (2024)
22. Immunotherapy of Cancers Comes of Age, Expert Review of Clinical Immunology (2017)
23. Development and Biological Assessment of Mmae-Trastuzumab Antibody–Drug Conjugates (Adcs), Breast Cancer (2021)
24. Immunotherapeutic Approaches for Cancer Therapy: An Updated Review, Artificial Cells# Nanomedicine and Biotechnology (2016)
25. Encapsulated Checkpoint Blocker Before Chemotherapy: The Optimal Sequence of Anti-Ctla-4 and Doxil Combination Therapy, International Journal of Nanomedicine (2020)
26. Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review, Current Cancer Therapy Reviews (2024)
27. Monoclonal Antibody-Based Therapeutics, Targeting the Epidermal Growth Factor Receptor Family: From Herceptin to Pan Her, Journal of Pharmacy and Pharmacology (2018)
28. Recent Progress in Immunotherapy of Breast Cancer Targeting the Human Epidermal Growth Factor Receptor 2 (Her2), Journal of Oncology Pharmacy Practice (2021)
29. Immunotherapy a New Hope for Cancer Treatment: A Review, Pakistan Journal of Biological Sciences (2018)
30. Tumor Immunology, Clinical Immunology (2022)
31. Eculizumab in Kidney Diseases, Journal of Nephropharmacology (2024)
32. The Promising Role of Monoclonal Antibodies for Gastric Cancer Treatment, Immunotherapy (2019)
33. Discovery of a Potential Biomarker for Immunotherapy of Melanoma: Plac1 As an Emerging Target, Immunopharmacology and Immunotoxicology (2020)
34. Immunopathology and Immunotherapy of Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
35. Current Trends in Targeted Therapy for Drug-Resistant Infections, Applied Microbiology and Biotechnology (2019)
36. Immune Checkpoint Inhibitors in Advanced Cutaneous Melanoma: A Systematic Review and Meta-Analysis of Efficacy and Review of Characteristics, Expert Review of Anticancer Therapy (2023)
37. Development of a Novel Inhibitory Chimeric Anti-Her2 Monoclonal Antibody, Iranian Journal of Immunology (2019)
38. Immunopathology and Immunotherapy of Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2015)